Spinal Muscular Atrophy
ICER will develop a report assessing the comparative clinical effectiveness and value of onasemnogene abeparvovec (Zolgensma®, Novartis AG/AveXis) and nusinersen (Spinraza®, Biogen) for treatment of spinal muscular atrophy (SMA).
Omni Parker House
60 School Street
Boston, MA 02108
The New England CEPAC will convene to deliberate and vote on ICER's report on treatments for SMA.